Podcasts about neurodegenerative diseases

For the nearly one million Americans living with Parkinson's disease, the space between neurology appointments can feel like a void — symptoms shift, medications need adjusting, and urgent questions pile up with nowhere to turn. That gap in continuous care is exactly the problem Rune Labs set out to solve. With its StrivePD app, Rune Labs has built a platform powered by FDA-cleared movement analysis and one of the largest real-world Parkinson's datasets in existence. Now, the company is going further — launching an AI caregiver directly inside the app: a coordinated system of specialized AI agents, including a Medication Assistant, Symptom Expert, and PD Coach, that deliver personalized, evidence-based guidance based on each patient's own real-time data. In this episode of Digital Health Talks, host Megan Antonelli sits down with Amy Gordon Franzen, the new CEO of Rune Labs, to explore how the company is redefining what it means to support patients not just in the clinic, but every moment of every day. From the science behind the platform to the policy, trust, and ethical questions that come with deploying AI in a chronic disease setting, this is a conversation about what the future of neurological care can actually look like — and who gets to shape it. Amy Gordon Franzen, CEO, Rune Labs Megan Antonelli, Chief Executive Officer, HealthIMPACT

Just about every animal with a backbone yawns (maybe even dinosaurs), but why we do it is still something of a mystery. A SciFri listener from Texas recently spotted some research that suggests yawning could play a role in clearing waste products from the brain, and asked us to get to the bottom of it. Biomechanical engineer Lynne Bilston, an author on that study, joins Flora to discuss the findings and what they could mean for neurodegenerative diseases like Alzheimer's. Plus, about a third of Americans aren't getting the recommended seven hours of sleep per night, according to a new CDC report. We check in with sleep researcher Stuti Jaiswal to break down the report and find out how to get a better night's sleep. Check out an MRI video of what yawning looks like inside the body. Guests:  Dr. Lynne Bilston is a biomechanical engineer at UNSW Sydney in Australia. Dr. Stuti Jaiswal is a physician scientist and co-director, education at Scripps Research Translational Institute in San Diego, California. Other episodes you may enjoy: Does Taping Your Mouth Shut Help You Sleep? The Brain's Glial Cells Might Be As Important As Neurons Want SciFri gear? Check out our new shop! Transcripts for each episode are available within 1-3 days at sciencefriday.com. Subscribe to this podcast. Follow our show on Instagram, TikTok, Facebook, and Bluesky @scifri and sign up for our newsletters. Got a science question that's keeping you up at night? Call us: 877-4-SCIFRI Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Neurodegenerative diseases such as Alzheimer's, Parkinson's, or ALS are often seen as something unstoppable. But instead of seeing them as essentially death sentences, they can certainly be treated. Thanks to nonstop tech innovation, these diseases can be dealt with not just in the brain itself but also in the immune system. Zach Gurick is joined by Dr. Ron Lane of HOPE-Neuron, who is pioneering a completely new approach to treating neurodegenerative diseases through a first-of-its-kind device design to reset the immune system and immune dysfunction at its source. He also opens up about his experiences as a caregiver, a father, and a husband who took care of his wife who was diagnosed with Alzheimer's, which motivated him to devote himself to this groundbreaking medical endeavor. The information presented in Fully Alive is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition or treatment and before making changes to your health regimen. Guests' opinions are their own and do not necessarily reflect those of the podcast host, production team, or sponsors.Love the show? Subscribe, rate, review, & share! https://www.shellpoint.org/podcast/

Scientific Sense ® by Gill Eapen: Dr. Alberto Espay is Professor and Chair of the Center for Parkinson's Disease at the University of Cincinnati. He has published over 400 peer-reviewed research articles, 40 book chapters and 10 books, including Common Movement Disorders Pitfalls.Please subscribe to the channel:http://scientificsense.world

Neurodegenerative conditions often develop over time. They are influenced by a combination of lifestyle, environmental, and biological factors. World-renowned integrative physician Lee Cowden, MD, guided us toward better health during the M3 Detox Experience, showing us the impact of mold, metals, and microbes toxicity on the body. Dr. Cowden is back to update us on how supporting the body holistically may help address underlying imbalances that affect brain health. By exploring approaches that focus on reducing inflammation, supporting detoxification pathways, and nourishing the nervous system, we can begin to see new possibilities for improving cognitive function and overall well-being. When we shift our focus from managing decline to supporting resilience, we open the door to hope, clarity, and a more proactive role in our health journey. Now you can listen commercial free at your leisure…Click here and let's grow together: Lee Cowden, MD, Reversing Neurodegenerative Diseases, Part 2 If you love this podcast episode, share it with a friend. The Lillian McDermott Radio Show/Classroom ~ When You Need a Friend… PREMIERE:  Telegram, Facebook, YouTube, WhenYouNeedaFriend.com SUBSCRIBE, LIKE, & FOLLOW:    Facebook, Instagram, X, Website, Odysee, BitChute, YouTube! LISTEN:  Amazon Podcast, Apple Podcasts, YouTube Music, Spotify, Pandora, TuneIn, iHeartRadio! CALL or TEXT: 407-373-5959 “You can take a pill, or You can take Responsibility!” ®

Invest Like the Best: Read the notes at at podcastnotes.org. Don't forget to subscribe for free to our newsletter, the top 10 ideas of the week, every Monday --------- My guest today is Alex Karnal. Alex is the co-founder and managing partner of Braidwell, a life sciences investment firm he built after spending 15 years at Deerfield Management. The frame we use throughout the episode is the health stack. Alex talks about how most of the diseases that will claim most of our lives are already addressable with medicines that exist today. We work through the five layers of what a defensive health strategy looks like, why GLP-1 medicines represent the first commercial proof that people are ready to be proactive about their health, and why PCSK9 inhibitors may ultimately be the more important drug class even though they get far less attention. We also get into the science and business of drug discovery itself — why most of the published literature that AI companies are training on cannot be replicated, what it would mean to have a truly agentic scientific lab running 24 hours a day, and why Alex believes we are now on a deterministic curve toward scientific superintelligence in biology. For the full show notes, transcript, and links to mentioned content, check out the episode page ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠here⁠⁠⁠⁠⁠.  ----- Become a Colossus member to get our quarterly print magazine and private audio experience, including exclusive profiles and early access to select episodes. Subscribe at ⁠colossus.com/subscribe⁠. ----- ⁠Ramp's⁠ mission is to help companies manage their spend in a way that reduces expenses and frees up time for teams to work on more valuable projects. Go to⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠ramp.com/invest⁠⁠ to sign up for free and get a $250 welcome bonus. ----- Trusted by thousands of businesses, ⁠Vanta⁠ continuously monitors your security posture and streamlines audits so you can win enterprise deals and build customer trust without the traditional overhead. Visit ⁠vanta.com/invest⁠.  ----- ⁠WorkOS⁠ is a developer platform that enables SaaS companies to quickly add enterprise features to their applications. Visit⁠⁠ ⁠WorkOS.com⁠⁠⁠ to transform your application into an enterprise-ready solution in minutes, not months. ----- ⁠Rogo⁠ is the AI platform for finance. They're building agents for Wall Street that are trained to understand how bankers and investors actually do work: from diligence and modeling, to turning analysis into deliverables. To learn more, visit rogo.ai/invest. ----- ⁠Ridgeline⁠ has built a complete, real-time, modern operating system for investment managers. It handles trading, portfolio management, compliance, customer reporting, and much more through an all-in-one real-time cloud platform. Visit⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ridgelineapps.com⁠. ----- Editing and post-production work for this episode was provided by The Podcast Consultant (⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://thepodcastconsultant.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠). Timestamps: (00:00:00) Welcome to Invest Like the Best (00:02:29) Intro: Alex Karnal (00:03:15) State of the Union: GLP1s and Life Sciences (00:07:01) The Health Stack Framework (00:12:49) Breaking Down the 5 Defensive Layers (00:21:18) GLP-1: What's Driving the Inflection (00:28:28) Diet vs. Drugs: Is Food Enough? (00:31:15) Barriers to Access: Complexity, Cost & Compliance (00:35:04) PCSK9: The Closest Thing to a Free Lunch (00:44:10) Alzheimer's & Neurodegenerative Disease (00:46:59) Cancer: Early Detection & New Treatments (00:54:49) Body Imaging & Diagnostic Trade-offs (00:56:31) How Drugs Are Discovered (01:02:39) AI in Drug Discovery (01:10:57) The Automated Lab of the Future (01:13:05) Peptides & Citizen Pharmacology (01:16:45) Alex's Background (01:28:25) Braidwell's Investment Approach (01:30:39) The Kindest Thing

My guest today is Alex Karnal. Alex is the co-founder and managing partner of Braidwell, a life sciences investment firm he built after spending 15 years at Deerfield Management. The frame we use throughout the episode is the health stack. Alex talks about how most of the diseases that will claim most of our lives are already addressable with medicines that exist today. We work through the five layers of what a defensive health strategy looks like, why GLP-1 medicines represent the first commercial proof that people are ready to be proactive about their health, and why PCSK9 inhibitors may ultimately be the more important drug class even though they get far less attention. We also get into the science and business of drug discovery itself — why most of the published literature that AI companies are training on cannot be replicated, what it would mean to have a truly agentic scientific lab running 24 hours a day, and why Alex believes we are now on a deterministic curve toward scientific superintelligence in biology. For the full show notes, transcript, and links to mentioned content, check out the episode page ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠here⁠⁠⁠⁠⁠.  ----- Become a Colossus member to get our quarterly print magazine and private audio experience, including exclusive profiles and early access to select episodes. Subscribe at ⁠colossus.com/subscribe⁠. ----- ⁠Ramp's⁠ mission is to help companies manage their spend in a way that reduces expenses and frees up time for teams to work on more valuable projects. Go to⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠ramp.com/invest⁠⁠ to sign up for free and get a $250 welcome bonus. ----- Trusted by thousands of businesses, ⁠Vanta⁠ continuously monitors your security posture and streamlines audits so you can win enterprise deals and build customer trust without the traditional overhead. Visit ⁠vanta.com/invest⁠.  ----- ⁠WorkOS⁠ is a developer platform that enables SaaS companies to quickly add enterprise features to their applications. Visit⁠⁠ ⁠WorkOS.com⁠⁠⁠ to transform your application into an enterprise-ready solution in minutes, not months. ----- ⁠Rogo⁠ is the AI platform for finance. They're building agents for Wall Street that are trained to understand how bankers and investors actually do work: from diligence and modeling, to turning analysis into deliverables. To learn more, visit rogo.ai/invest. ----- ⁠Ridgeline⁠ has built a complete, real-time, modern operating system for investment managers. It handles trading, portfolio management, compliance, customer reporting, and much more through an all-in-one real-time cloud platform. Visit⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ridgelineapps.com⁠. ----- Editing and post-production work for this episode was provided by The Podcast Consultant (⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://thepodcastconsultant.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠). Timestamps: (00:00:00) Welcome to Invest Like the Best (00:02:29) Intro: Alex Karnal (00:03:15) State of the Union: GLP1s and Life Sciences (00:07:01) The Health Stack Framework (00:12:49) Breaking Down the 5 Defensive Layers (00:21:18) GLP-1: What's Driving the Inflection (00:28:28) Diet vs. Drugs: Is Food Enough? (00:31:15) Barriers to Access: Complexity, Cost & Compliance (00:35:04) PCSK9: The Closest Thing to a Free Lunch (00:44:10) Alzheimer's & Neurodegenerative Disease (00:46:59) Cancer: Early Detection & New Treatments (00:54:49) Body Imaging & Diagnostic Trade-offs (00:56:31) How Drugs Are Discovered (01:02:39) AI in Drug Discovery (01:10:57) The Automated Lab of the Future (01:13:05) Peptides & Citizen Pharmacology (01:16:45) Alex's Background (01:28:25) Braidwell's Investment Approach (01:30:39) The Kindest Thing

The blood-brain barrier (BBB) is a vital protective mechanism that shields the brain from harmful substances, but it also poses a significant challenge in treating neurological diseases. For patients with aggressive brain tumors or neurodegenerative conditions, the BBB can prevent life-saving therapies and chemotherapeutic agents from reaching their targets, leaving limited treatment options. In this episode of Curing with Sound, we speak with Ying Meng, MD, PhD, a neurosurgeon and scientist at Sunnybrook Health Sciences Centre and the University of Toronto. Dr. Meng is at the forefront of advancing noninvasive brain therapies, leading efforts to translate preclinical focused ultrasound research into clinical application. She shares insights from groundbreaking clinical trials using focused ultrasound to enable targeted drug delivery across the BBB for conditions such as pediatric gliomas and breast cancer metastases, as well as insights on liquid biopsy biomarkers. Discussion highlights: The Future of Accessible Treatment: Dr. Meng's perspective on the next decade of innovation, including the potential shift of focused ultrasound procedures from specialized MRI environments to more accessible, bedside settings within standard infusion centers—broadening patient access and improving treatment tolerability. Center of Excellence (COE): Established as a COE in 2016, the Sunnybrook Health Sciences Centre is conducting research for focused ultrasound in neurology, neurosurgery, urology, orthopedics, gynecology, radiation oncology, and biomedical engineering. The COE program recognizes luminary sites for their excellence in translational and clinical research, training, and patient care. EPISODE TRANSCRIPT ---------------------------- QUESTIONS? Email podcast@fusfoundation.org if you have a question or comment about the show, or if you would you like to connect about future guest appearances.  Email info@fusfoundation.org if you have questions about focused ultrasound or the Foundation.  FUSF SOCIAL MEDIA LinkedIn X Facebook Instagram TikTok YouTube FUSF WEBSITE https://www.fusfoundation.org FOCUSED ULTRASOUND TREATMENT SITES https://www.fusfoundation.org/the-technology/treatment-sites/ SIGN UP FOR OUR FREE NEWSLETTER https://www.fusfoundation.org/newsletter-signup/ READ THE LATEST NEWSLETTER https://www.fusfoundation.org/the-foundation/news-media/newsletter/ DOWNLOAD "THE TUMOR" BY JOHN GRISHAM (FREE E-BOOK) https://www.fusfoundation.org/read-the-tumor-by-john-grisham/    

In this episode, Lucas Aoun sits down with Alex Kikel to unpack the next wave of peptides and cutting-edge biohacking therapies, reshaping performance and longevity medicine. They dive into emerging compounds beyond the mainstream GLP-1 and BPC-157 conversation, exploring mitochondrial-targeting peptides, regenerative signaling molecules, cognitive-enhancement stacks, and the evolving landscape of immune-modulating and tissue-repair agents.Relevant Links:Alex's website: https://theprepcoach.com/ Get Coaching With Lucas Aoun Here: https://www.boostyourbiology.com/product/coaching Disclaimer:The information provided in this podcast episode is for entertainment purposes and is NOT MEDICAL ADVICE. If you have any questions about your health, contact a medical professional. This content is strictly the opinions of Lucas Aoun and is for informational and entertainment purposes only. It is not intended to provide medical advice or to take the place of medical advice or treatment from a personal physician. All viewers of this content are advised to consult with their doctors or qualified health professionals regarding specific health questions. Neither Lucas Aoun nor the publisher of this content takes responsibility for possible health consequences of any person or persons reading or following the information in this content. All consumers of this content especially taking prescription or over-the-counter medications should consult their physician before beginning any nutritional, supplement or lifestyle program.Chapters00:00 Introduction to Biohacking and Novel Protocols02:05 Alex's Background and Journey04:40 Exploring A New Device for Brain Health07:56 Clotho Protein Peptide: Mechanisms and Benefits11:55 Applications of Clotho in Health and Disease13:49 VD-11: A New Compound for Healing and Repair17:16 FOXO3: The Longevity and Anti-Tumor Molecule34:27 Immune Support Protocols for Athletes36:11 Understanding PSSD and Its Complexities39:09 The Role of AI in Drug Development41:11 Advanced Recovery Protocols and Peptides48:58 Blood Flow Optimization and Nitric Oxide55:25 Neurodegenerative Diseases and Glutamate Imbalance01:03:44 Future Research Directions in Mitochondrial Health Hosted on Acast. See acast.com/privacy for more information.

Alzheimer's disease unfolds over many years through a complex interplay of amyloid, tau, genetics, lipid biology, and the brain's immune response. John Hardy, Ph.D., explains how rare inherited forms of Alzheimer's disease helped shape current thinking about how the disease begins, then connects those discoveries to broader questions about late onset disease and why it develops differently across people. Hardy shows that amyloid and tau are linked but not identical, and argues that problems with protein buildup and clearance both matter in understanding the disease. He also emphasizes that Alzheimer's is not a single event but a long process, which makes prediction, diagnosis, and treatment especially difficult. While current amyloid-targeting therapies can help and show measurable benefit, Hardy says they do not stop the disease, underscoring the need for earlier diagnosis, better treatments, and wider access to care Series: "Shiley Endowed Lecture" [Health and Medicine] [Show ID: 41250]

Alzheimer's disease unfolds over many years through a complex interplay of amyloid, tau, genetics, lipid biology, and the brain's immune response. John Hardy, Ph.D., explains how rare inherited forms of Alzheimer's disease helped shape current thinking about how the disease begins, then connects those discoveries to broader questions about late onset disease and why it develops differently across people. Hardy shows that amyloid and tau are linked but not identical, and argues that problems with protein buildup and clearance both matter in understanding the disease. He also emphasizes that Alzheimer's is not a single event but a long process, which makes prediction, diagnosis, and treatment especially difficult. While current amyloid-targeting therapies can help and show measurable benefit, Hardy says they do not stop the disease, underscoring the need for earlier diagnosis, better treatments, and wider access to care Series: "Shiley Endowed Lecture" [Health and Medicine] [Show ID: 41250]

Alzheimer's disease unfolds over many years through a complex interplay of amyloid, tau, genetics, lipid biology, and the brain's immune response. John Hardy, Ph.D., explains how rare inherited forms of Alzheimer's disease helped shape current thinking about how the disease begins, then connects those discoveries to broader questions about late onset disease and why it develops differently across people. Hardy shows that amyloid and tau are linked but not identical, and argues that problems with protein buildup and clearance both matter in understanding the disease. He also emphasizes that Alzheimer's is not a single event but a long process, which makes prediction, diagnosis, and treatment especially difficult. While current amyloid-targeting therapies can help and show measurable benefit, Hardy says they do not stop the disease, underscoring the need for earlier diagnosis, better treatments, and wider access to care Series: "Shiley Endowed Lecture" [Health and Medicine] [Show ID: 41250]

Alzheimer's disease unfolds over many years through a complex interplay of amyloid, tau, genetics, lipid biology, and the brain's immune response. John Hardy, Ph.D., explains how rare inherited forms of Alzheimer's disease helped shape current thinking about how the disease begins, then connects those discoveries to broader questions about late onset disease and why it develops differently across people. Hardy shows that amyloid and tau are linked but not identical, and argues that problems with protein buildup and clearance both matter in understanding the disease. He also emphasizes that Alzheimer's is not a single event but a long process, which makes prediction, diagnosis, and treatment especially difficult. While current amyloid-targeting therapies can help and show measurable benefit, Hardy says they do not stop the disease, underscoring the need for earlier diagnosis, better treatments, and wider access to care Series: "Shiley Endowed Lecture" [Health and Medicine] [Show ID: 41250]

Alzheimer's disease unfolds over many years through a complex interplay of amyloid, tau, genetics, lipid biology, and the brain's immune response. John Hardy, Ph.D., explains how rare inherited forms of Alzheimer's disease helped shape current thinking about how the disease begins, then connects those discoveries to broader questions about late onset disease and why it develops differently across people. Hardy shows that amyloid and tau are linked but not identical, and argues that problems with protein buildup and clearance both matter in understanding the disease. He also emphasizes that Alzheimer's is not a single event but a long process, which makes prediction, diagnosis, and treatment especially difficult. While current amyloid-targeting therapies can help and show measurable benefit, Hardy says they do not stop the disease, underscoring the need for earlier diagnosis, better treatments, and wider access to care Series: "Shiley Endowed Lecture" [Health and Medicine] [Show ID: 41250]

In this episode, we dive into the future of brain repair with Dr. Ruslan Rust, Assistant Professor of Research Physiology and Neuroscience at the Keck School of Medicine at USC. With over 15 years of experience in translational neuroscience, Dr. Rust is developing cutting-edge gene-edited, induced pluripotent stem cell (iPSC)-derived therapies aimed at overcoming the toughest challenges in brain regeneration, including crossing the blood-brain barrier, immune rejection, and long-term safety. Dr. Rust's pioneering work combines advanced stem cell biology, genetic engineering, and AI-driven analytics to transform the treatment landscape for stroke recovery and neurodegenerative diseases like Alzheimer's. In this conversation, we explore: The current limitations of stem cell therapies in treating stroke and neurodegeneration. How stem cells are harvested and engineered to navigate the blood-brain barrier. The role of gene-edited iPSC-derived cells in enhancing brain repair. How AI and single-cell omics are accelerating breakthroughs in neurodegeneration. With his background in bio-entrepreneurship and scientific leadership, Dr. Rust offers a practical approach to turning innovative neuroscience into viable therapies. Tune in for a glimpse into the future of stroke recovery and Alzheimer's treatment. To follow Dr. Ruslan Rust's research, visit his academic website or follow him on X. Episode also available on Apple Podcasts: https://apple.co/38oMlMr 

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of transformative events shaping the industry, from groundbreaking drug approvals to strategic corporate maneuvers.Recently, the U.S. Food and Drug Administration (FDA) granted approval for Eli Lilly's new GLP-1 receptor agonist pill, Foundayoby, marking a significant milestone as it's the first new molecular entity to be cleared under the FDA's Commissioners National Priority Voucher Program. This program is designed to expedite the review process for drugs addressing critical needs or representing substantial advancements in treatment. Foundayoby's entry into the market provides a competitive edge against Novo Nordisk's products, offering a convenient oral alternative in the management of type 2 diabetes and obesity. Clinical trials have shown that this oral formulation maintains efficacy comparable to injectable peptides while improving patient adherence due to its ease of use. This development not only broadens therapeutic options but also emphasizes the growing trend towards patient-centric formulations in diabetes management.In related news, Eli Lilly has also received FDA approval for its oral obesity medication, Orforglipron, marketed as Foundayo. This approval further intensifies the rivalry with Novo Nordisk, which launched its oral therapy Wegovy earlier. Orforglipron's clinical trials demonstrated significant weight reduction in patients, highlighting pharmacotherapy's rising importance as an option for individuals struggling with obesity despite lifestyle modifications. The convenience of an oral formulation is expected to enhance patient compliance and long-term success, addressing a key challenge in obesity management.In strategic corporate news, Korsana Biosciences is making waves by entering public markets through a reverse merger with Cyclerion. This move highlights ongoing interest and investment in neurodegenerative diseases like Alzheimer's. In contrast, KBP Biosciences faces legal challenges as it seeks to reclaim ownership of heart drug Ocedurenone from Novo Nordisk after a failed billion-dollar deal. Such cases underscore the complexities inherent in pharmaceutical collaborations.Regulatory scrutiny continues to play a crucial role in shaping industry dynamics. The FDA extended its review period for Orca Bio's novel cell therapy for blood cancers by three months. This delay reflects rigorous regulatory requirements for innovative treatments poised to transform oncology care paradigms. Meanwhile, Iterum Therapeutics is winding down operations following unsuccessful sales of its antibiotic Orlynvah, highlighting financial sustainability challenges within the antibiotic market.Safety remains paramount as evidenced by concerns over Amgen's Tavneos after reports of serious liver injuries linked to its use. The FDA has identified 76 cases, including fatalities, underscoring the importance of post-market surveillance and risk management in ensuring patient safety.In terms of mergers and acquisitions, Eli Lilly's strategic acquisition of Centessa Pharmaceuticals for $6.3 billion signifies its entry into the sleep disorder market. Biogen followed suit by acquiring Apellis Pharmaceuticals for $5.6 billion to strengthen its kidney disease expertise. These moves reflect a broader trend where pharmaceutical giants are diversifying portfolios through acquisitions targeting niche therapeutic areas.On the technological front, partnerships leveraging artificial intelligence (AI) are gaining traction. Bristol Myers Squibb's collaboration with Faro Technologies aims to refine clinical trials using AI, while Merck & Co.'s partnership with Infinimmune focuses on antibody discovery innovations.Financially, Blackstone's record-breaking $6.3 billion life sciences fund highlights robust invSupport the show

Brain science does not stand still. New research continues to reshape how we think about memory, prevention, nutrition, and lifelong cognitive health.In this special Brain Week 2026 episode of the Let's Talk Brain Health! Podcast, your hosts brought together a panel of experts across neurology, neuropsychology, nutrition, sensory therapies, and aging science to discuss what is new, what is promising, and what still needs more evidence.This conversation focuses on separating hype from science. You will hear where the strongest research is emerging, what early warning signs deserve more attention, and how everyday habits influence brain health across the lifespan.If you want to stay current on brain health science and understand what actions are worth your attention right now, this episode brings the latest updates directly from the experts.What You Will Learn in This EpisodeEarly brain health signals adults often overlookWhy prevention starts decades before symptoms appear How sleep, smell changes, and hearing loss connect to brain healthWhat new research says about the MIND diet and dementia riskWhy personalized risk reduction matters more than one-size adviceThe role of caffeine and nutrition in cognitive performanceWhat emerging research says about sensory stimulation and brain functionWhy following evidence over trends protects your brain healthKey Topics CoveredEarly Detection and PreventionLearn why subtle changes such as sleep disruption, smell loss, and metabolic health may signal future neurological risk and why early action matters.Cognitive Aging and Risk ReductionUnderstand how lifelong learning, education, and cognitive engagement build resilience against cognitive decline.Nutrition and Brain HealthExplore the latest findings on the MIND diet, anti-inflammatory nutrition, and emerging areas like mushrooms and metabolic health.Brain Performance and Fueling CognitionLearn how caffeine and metabolic health influence daily brain performance.Emerging Therapies and Brain StimulationHear updates on areas such as 40 Hz sensory stimulation and aromatherapy research, and where the evidence currently stands.Key TakeawaysBrain health is built across decades, not just later in life.Prevention science continues to strengthen around lifestyle factors such as cardiovascular health, hearing health, sleep quality, and nutrition.There is no single solution for brain health. Personal risk factors matter.Patterns matter more than perfection when it comes to brain-healthy habits. Following credible science helps protect you from misinformation.Earn FREE CEs Join the Learn at Pinnacle app ⁠to earn FREE CE Credit for listening to this episode!Featured Expert GuestsDr. Kellyann Niotis, MD – Preventive Neurology and  The Institute for Neurodegenerative Diseases of Florida Dr. Mitchell Clionsky, Ph.D. – Clinical Neuropsychology and author of Dementia Prevention: Using Your Head to Save Your BrainMaggie Moon, MS, RD – Brain health nutrition and author of the MIND dietDr. Richard Gold, Ph.D. – 40 Hz sensory stimulation and applied neuroscience from Metta Mindfulness MeditationDr. Jenna Stedman, DCN – Performance nutrition at Master Nutrition LabPatricia Faust, MGS – Clinical aromatherapy and aging brain health at My Boomer BrainPrevious Podcast Episodes from Our PanelistsEpisode 58: Preventive Neurology: Brain Care Today to Protect Tomorrow with Dr. Kellyann Niotis, MDEpisode 3: Dementia Prevention: Using Your Head to Save Your Brain with Dr. Emily Clionsky, M.D. and Dr. Mitch Clionsky, Ph.D.Episode 42: The MIND Diet Update: A Scientific Approach for Brain Health & Dementia Prevention with Maggie Moon, MS, RD Episode 6: Brain Beats: How Sound Influences Cognition with Dr. Richard Gold, Ph.D.Episode 48: Enhancing Cognitive Performance Through Nutrition with Dr. Jenna Stedman, DCN Episode 36: Essential Oils for Brain Health: Insights From A Clinical Aromatherapist, Patricia Faust, MGS

David Stamler, CEO of Alterity Therapeutics, is developing a drug to treat multiple system atrophy (MSA), a rare and rapidly progressing neurodegenerative disease that often presents as Parkinson's disease but is distinct and more aggressive. There is no single genetic cause or specific biomarker, making accurate diagnosis a significant challenge. The lead drug is a novel small molecule designed to manage excess reactive iron in the brain, which drives the disease, and may be effective for other neurodegenerative diseases involving iron dysregulation. David explains, "Multiple system atrophy is a rare disease, and that's part of the reason people may not know so much about it. It is a neurodegenerative disease, and as the name implies, there are multiple regions of the brain that are affected, hence the term multiple systems that are governed by those regions of the brain. And as the disease progresses, some of these regions degenerate, and you get abnormal function in various areas."   "Now, we like to characterize the disease as a Parkinsonian disorder, which means early on, it can look like Parkinson's disease. And that's kind of a good descriptor to help people understand what it might look like, but it's distinct from Parkinson's disease, and it progresses a lot faster, a lot more rapidly. So it's a disease that people don't know about, probably because no one famous has been diagnosed with MSA, although I'm sure various famous people have probably had the disease and maybe didn't know it."  #AlterityTherapeutics #MultipleSystemAtrophy #MSAAwareness #NeurodegenerativeDisease #Biotech #Phase3 #Neurology #MSA #ClinicalTrials #AlterityTherapeutics #ATH434 #Biotech #RareDisease #Neurodegeneration #DrugDevelopment #MedicalBreakthrough #IronChaperone Alteritytx.com Download the transcript here  

David Stamler, CEO of Alterity Therapeutics, is developing a drug to treat multiple system atrophy (MSA), a rare and rapidly progressing neurodegenerative disease that often presents as Parkinson's disease but is distinct and more aggressive. There is no single genetic cause or specific biomarker, making accurate diagnosis a significant challenge. The lead drug is a novel small molecule designed to manage excess reactive iron in the brain, which drives the disease, and may be effective for other neurodegenerative diseases involving iron dysregulation. David explains, "Multiple system atrophy is a rare disease, and that's part of the reason people may not know so much about it. It is a neurodegenerative disease, and as the name implies, there are multiple regions of the brain that are affected, hence the term multiple systems that are governed by those regions of the brain. And as the disease progresses, some of these regions degenerate, and you get abnormal function in various areas."   "Now, we like to characterize the disease as a Parkinsonian disorder, which means early on, it can look like Parkinson's disease. And that's kind of a good descriptor to help people understand what it might look like, but it's distinct from Parkinson's disease, and it progresses a lot faster, a lot more rapidly. So it's a disease that people don't know about, probably because no one famous has been diagnosed with MSA, although I'm sure various famous people have probably had the disease and maybe didn't know it."  #AlterityTherapeutics #MultipleSystemAtrophy #MSAAwareness #NeurodegenerativeDisease #Biotech #Phase3 #Neurology #MSA #ClinicalTrials #AlterityTherapeutics #ATH434 #Biotech #RareDisease #Neurodegeneration #DrugDevelopment #MedicalBreakthrough #IronChaperone Alteritytx.com Listen to the podcast here

Send us Fan MailWe love discussing oral systemic health, so we could not be more excited to chat with Anne O. Rice on this week's episode

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of significant events and trends shaping the industry landscape, offering insight into the dynamic interplay between scientific innovation, regulatory challenges, and strategic growth.Starting with the recent departure of Vinay Prasad from the U.S. Food and Drug Administration, particularly from his role as director of the Center for Biologics Evaluation and Research (CBER). Prasad's tenure, though brief, left an indelible mark characterized by controversy and debate over regulatory decisions. His leadership coincided with significant advancements in biologics and gene editing technologies, like CRISPR, highlighting the complexities in balancing innovation with safety standards. Under Prasad's guidance, the FDA faced challenges in navigating these rapid advancements while maintaining rigorous oversight to ensure that new therapies are both effective and safe for public use. Prasad's resignation signals potential shifts in regulatory philosophy at CBER. The biotech industry is watching closely to see how new leadership will influence ongoing and future evaluations of biologics. The change presents an opportunity to reassess how regulatory bodies can better adapt to scientific advancements while ensuring that patient safety remains paramount. The issues faced during Prasad's tenure underscore the need for transparent decision-making and open communication with stakeholders, which are vital for maintaining trust in regulatory processes.Meanwhile, Pfizer has made a strategic entry into the Chinese obesity market with the approval of a GLP-1 drug developed alongside Sciwind Biosciences. This approval represents not only a significant step for Pfizer but also underscores a broader global focus on obesity management. The efficacy of GLP-1 receptor agonists in weight regulation has opened up new market opportunities, highlighting the growing importance of metabolic health solutions in addressing public health challenges.In other news, Johnson & Johnson's Tecvayli-Darzalex combination therapy has received its third national priority recognition from the FDA for treating multiple myeloma. This recognition reflects promising Phase 3 trial results and underscores the critical role of innovative combination therapies in improving outcomes for complex hematologic malignancies. The success of such therapies illustrates how targeted approaches can significantly enhance treatment efficacy and patient quality of life.Strategic acquisitions continue to reshape industry dynamics. Servier's $2.5 billion acquisition of Day One Biopharmaceuticals aims to strengthen its rare cancer portfolio, including a promising glioma drug, Ojemda. This move highlights Servier's commitment to addressing unmet needs in pediatric oncology and rare diseases, emphasizing a broader industry trend towards focusing on niche therapeutic areas with high potential impact.Regulatory activities are gaining momentum as well, with the FDA set to end a nine-month hiatus in advisory committee meetings by reviewing AstraZeneca's oral selective estrogen receptor degrader Truqa. As AstraZeneca seeks to enhance its oncology pipeline, this review signals ongoing innovation in hormone-based cancer therapies and reflects a renewed emphasis on bringing novel treatments to market efficiently.Additionally, Glenmark Pharmaceuticals has achieved a significant milestone with FDA approval for its generic version of GSK's asthma inhaler Flovent. This development exemplifies efforts to improve access to respiratory treatments by providing cost-effective alternatives to branded medications, potentially reducing healthcare costs while enhancing patient access.On an international scale, Taiwan has announced a substantial investment plan aimed at bolstering its drugSupport the show

For decades, Alzheimer's disease was treated as an unavoidable consequence of aging. In this episode of Research Renaissance, Dr. Jessica Rexach explains why that framing is no longer true.Drawing on 20 years at the intersection of clinical neurology, genetics, and experimental neuroscience, Dr. Rexach walks us through a profound shift in the field. Today, scientists can model human brain circuits, measure Alzheimer's pathology through blood-based biomarkers, and study why some brains remain cognitively resilient even with disease pathology present.The science, she argues, is ready. The real question is whether society will commit the resources needed to finish the job.Key TakeawaysAlzheimer's research has moved from broad hypotheses to precise, testable mechanismsBlood-based biomarkers have transformed clinical trials and early detectionBrain resilience, not just pathology, may hold the key to preventionCOVID-era investments unintentionally accelerated dementia research toolsThe biggest risk now is not scientific failure, but loss of funding and momentumGuest InformationDr. Jessica RexachAssistant Professor, UCLA2024 Toffler Scholar

What if helping the immune system find balance could meaningfully slow disease progression for diseases like ALS or Alzheimer's? In this episode of Rx for Biotech, host Chris Leidli sits down with Arun Swaminathan, CEO of Coya Therapeutics, to talk about a new and hopeful approach to treating neurodegenerative diseases by calming harmful inflammation in the body. This conversation offers a hopeful look at how science is working to improve quality of life for patients and families facing neurodegenerative disease. Arun also shares insights from his 20+ years in biotech leadership, including what it takes to advance novel immunology science in high-unmet-need indications and build a product pipeline across neurodegenerative, autoimmune, and inflammatory diseases.

Stem cell science is reshaping treatment for complex disorders of the brain and spinal cord. Researchers develop cell based therapies to replace lost dopaminergic neurons in Parkinson's disease, fill gaps across spinal cord injuries, and calm seizure networks in refractory epilepsy by restoring the balance of inhibition and excitation. Teams test immune cell therapies against Epstein Barr virus infected B cells in multiple sclerosis and collaborate to move treatments across the blood brain barrier to reach diseased cells. Clinicians combine imaging in the operating room, surgical tools, and research on biological age and the pace of aging to understand disease and guide treatment. Patient advocates describe challenges and hopes for better options, and contemporary art reflects on perception in digital and physical worlds. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40992]

Stem cell science is reshaping treatment for complex disorders of the brain and spinal cord. Researchers develop cell based therapies to replace lost dopaminergic neurons in Parkinson's disease, fill gaps across spinal cord injuries, and calm seizure networks in refractory epilepsy by restoring the balance of inhibition and excitation. Teams test immune cell therapies against Epstein Barr virus infected B cells in multiple sclerosis and collaborate to move treatments across the blood brain barrier to reach diseased cells. Clinicians combine imaging in the operating room, surgical tools, and research on biological age and the pace of aging to understand disease and guide treatment. Patient advocates describe challenges and hopes for better options, and contemporary art reflects on perception in digital and physical worlds. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40992]

Stem cell science is reshaping treatment for complex disorders of the brain and spinal cord. Researchers develop cell based therapies to replace lost dopaminergic neurons in Parkinson's disease, fill gaps across spinal cord injuries, and calm seizure networks in refractory epilepsy by restoring the balance of inhibition and excitation. Teams test immune cell therapies against Epstein Barr virus infected B cells in multiple sclerosis and collaborate to move treatments across the blood brain barrier to reach diseased cells. Clinicians combine imaging in the operating room, surgical tools, and research on biological age and the pace of aging to understand disease and guide treatment. Patient advocates describe challenges and hopes for better options, and contemporary art reflects on perception in digital and physical worlds. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40992]

Stem cell science is reshaping treatment for complex disorders of the brain and spinal cord. Researchers develop cell based therapies to replace lost dopaminergic neurons in Parkinson's disease, fill gaps across spinal cord injuries, and calm seizure networks in refractory epilepsy by restoring the balance of inhibition and excitation. Teams test immune cell therapies against Epstein Barr virus infected B cells in multiple sclerosis and collaborate to move treatments across the blood brain barrier to reach diseased cells. Clinicians combine imaging in the operating room, surgical tools, and research on biological age and the pace of aging to understand disease and guide treatment. Patient advocates describe challenges and hopes for better options, and contemporary art reflects on perception in digital and physical worlds. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40992]

Stem cell science is reshaping treatment for complex disorders of the brain and spinal cord. Researchers develop cell based therapies to replace lost dopaminergic neurons in Parkinson's disease, fill gaps across spinal cord injuries, and calm seizure networks in refractory epilepsy by restoring the balance of inhibition and excitation. Teams test immune cell therapies against Epstein Barr virus infected B cells in multiple sclerosis and collaborate to move treatments across the blood brain barrier to reach diseased cells. Clinicians combine imaging in the operating room, surgical tools, and research on biological age and the pace of aging to understand disease and guide treatment. Patient advocates describe challenges and hopes for better options, and contemporary art reflects on perception in digital and physical worlds. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40992]

Stem cell science is reshaping treatment for complex disorders of the brain and spinal cord. Researchers develop cell based therapies to replace lost dopaminergic neurons in Parkinson's disease, fill gaps across spinal cord injuries, and calm seizure networks in refractory epilepsy by restoring the balance of inhibition and excitation. Teams test immune cell therapies against Epstein Barr virus infected B cells in multiple sclerosis and collaborate to move treatments across the blood brain barrier to reach diseased cells. Clinicians combine imaging in the operating room, surgical tools, and research on biological age and the pace of aging to understand disease and guide treatment. Patient advocates describe challenges and hopes for better options, and contemporary art reflects on perception in digital and physical worlds. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40992]

The woman who lived to 118 years old had one remarkable characteristic that scientists couldn't ignore; her gut microbiome resembled that of a 35-year-old. I'm here today with Anders Corbett, CEO of Craft Microbiome, unpacking the science of banking your young bacteria before age-related decline sets in, and how specific bacterial strains are now being correlated to neurodegenerative diseases years before symptoms appear. Your genetic predisposition to Alzheimer's or Parkinson's may not be your destiny at all.  CLICK HERE TO BECOME GARYS VIP!: https://bit.ly/4ai0Xwg Check out Anders Products here: www.craftmicrobiome.com  Connect with Anders Corbett Website: https://bit.ly/495Viuq  Instagram: https://bit.ly/4qz2Uvd  Facebook: https://bit.ly/44XmbOH  LinkedIn: https://bit.ly/44Xmjh9  Thank you to our partners H2TABS: “ULTIMATE10” FOR 10% OFF: https://bit.ly/4hMNdgg BODYHEALTH: “ULTIMATE20” FOR 20% OFF: http://bit.ly/4e5IjsV BAJA GOLD: "ULTIMATE10" FOR 10% OFF: https://bit.ly/3WSBqUa COLD LIFE: THE ULTIMATE HUMAN PLUNGE: https://bit.ly/4eULUKp WHOOP: JOIN AND GET 1 FREE MONTH!: https://bit.ly/3VQ0nzW AION: “ULTIMATE10” FOR 10% OFF: https://bit.ly/4h6KHAD A-GAME: “ULTIMATE15” FOR 15% OFF: http://bit.ly/4kek1ij PEPTUAL: “TUH10” FOR 10% OFF: https://bit.ly/4mKxgcn CARAWAY: “ULTIMATE” FOR 10% OFF: https://bit.ly/3Q1VmkC HEALF: 10% OFF YOUR ORDER: https://bit.ly/41HJg6S RHO NUTRITION: “ULTIMATE15” FOR 15% OFF: https://bit.ly/44fFza0 GOPUFF: GET YOUR FAVORITE SNACK!: https://bit.ly/4obIFDC GENETIC METHYLATION TEST (UK ONLY): https://bit.ly/48QJJrk GENETIC TEST (USA ONLY): ⁠https://bit.ly/3Yg1Uk9 Watch  the “Ultimate Human Podcast” every Tuesday & Thursday at 9AM EST: YouTube: https://bit.ly/3RPQYX8 Podcasts: https://bit.ly/3RQftU0 Connect with Gary Brecka Instagram: https://bit.ly/3RPpnFs TikTok: https://bit.ly/4coJ8fo X: https://bit.ly/3Opc8tf Facebook: https://bit.ly/464VA1H LinkedIn: https://bit.ly/4hH7Ri2 Website: https://bit.ly/4eLDbdU Merch: https://bit.ly/4aBpOM1 Newsletter: https://bit.ly/47ejrws Ask Gary: https://bit.ly/3PEAJuG Timestamps 00:00 Intro of Show 02:03 Anders Corbett's Background 09:27 How Does Your Gut Bacteria Make Your Muscles Stronger? 16:32 Analysing Gut Bacteria Procedure and Treatment 26:27 Addressing the Symptoms 30:38 Working with NBA and Elite Athletes 36:57 Crafting Your Microbiome (on Your Own Goals) 40:07 Where to Start (When You Have Gut Inflammation)? 48:49 Treating Children's Skin Diseases 57:09 Successful Patients' Cases 1:05:36 Mitigating the Risks of Neurodegenerative Diseases  1:08:44 What's Next for Craft Microbiome? 1:13:30 Restoring Healthy Physiology 1:18:26 Where to Start on Your Health Journey? 1:23:52 What does it mean to you to be an Ultimate Human? The Ultimate Human with Gary Brecka Podcast is for general informational purposes only and does not constitute the practice of medicine, nursing or other professional health care services, including the giving of medical advice, and no doctor/patient relationship is formed. The use of information on this podcast or materials linked from this podcast is at the user's own risk. The Content of this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Users should not disregard or delay in obtaining medical advice for any medical condition they may have and should seek the assistance of their health care professionals for any such conditions. Learn more about your ad choices. Visit megaphone.fm/adchoices

In this episode, we hear from not one, but two Titans of Science, together. And that's because Ed Wild and Sarah Tabrizi are neuroscientists, neurologists and long-time collaborators both based at University College London. They've devoted much of their careers to understanding Huntington's Disease. Chris Smith went to visit them in London... Like this podcast? Please help us by supporting the Naked Scientists

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Let's dive right into some of the latest breakthroughs and shifts shaping the industry landscape.In recent weeks, the pharmaceutical world has been abuzz with news of a groundbreaking new therapy that offers hope for patients with a rare genetic disorder. This novel treatment utilizes cutting-edge gene-editing technology, specifically CRISPR-Cas9, to target and correct genetic mutations at their source. By precisely editing the DNA within patient cells, this therapy promises not only to alleviate symptoms but potentially cure the disorder altogether. The implications of this development are profound, as it opens new avenues for treating a host of other genetic diseases that have long been considered incurable. Researchers are optimistic that this could herald a new era in personalized medicine.Meanwhile, on the regulatory front, significant progress has been made with the approval of a new cancer drug by the FDA. This drug, which has shown remarkable efficacy in clinical trials, targets a specific protein that is overexpressed in certain types of tumors. By inhibiting this protein, the drug effectively halts tumor growth and reduces metastasis. Such targeted therapies represent a shift towards more precise cancer treatments, minimizing damage to healthy cells and reducing side effects for patients. The FDA's decision underscores the importance of innovative approaches in oncology and sets a precedent for future approvals.In another exciting development, a recent phase III clinical trial has yielded promising results for a new Alzheimer's treatment. This monoclonal antibody targets amyloid-beta plaques in the brain, which are believed to be a key factor in the progression of Alzheimer's disease. The trial showed significant slowing of cognitive decline in patients who received the treatment compared to those on placebo. While there is still much to learn about the pathogenesis of Alzheimer's, these findings offer renewed hope for patients and their families and highlight the potential for antibody-based therapies in neurodegenerative diseases.Turning our attention to industry trends, there's a growing emphasis on sustainability within pharmaceutical manufacturing processes. Many companies are now investing in green chemistry, which focuses on designing products and processes that minimize environmental impact and reduce waste. This shift is not only driven by regulatory pressures but also by increasing consumer demand for eco-friendly products. By adopting sustainable practices, pharmaceutical companies are working to ensure that their contributions to global health do not come at the expense of planetary health.Finally, let's explore an intriguing trend within biotech: the rise of artificial intelligence (AI) and machine learning in drug discovery. These technologies are being harnessed to analyze vast datasets more efficiently than ever before, enabling researchers to identify potential drug candidates with greater speed and accuracy. AI-driven platforms can model complex biological interactions, predict molecular behavior, and even design novel compounds. As this field continues to evolve, it promises to revolutionize how new drugs are discovered and developed, potentially reducing time-to-market and bringing therapies to patients faster.These stories illustrate just how dynamic and innovative the pharmaceutical and biotech industries continue to be. With every breakthrough and development, there comes new hope for tackling some of humanity's most challenging health issues. Thank you for joining us today on Pharma Daily as we continue to explore these exciting advancements in science and medicine.Support the show

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world.Today, we dive into the latest breakthroughs and innovations shaping our industry. We start with a remarkable advancement in Alzheimer's disease treatment. A recent clinical trial has demonstrated significant progress in slowing cognitive decline among patients suffering from this challenging condition. The study, which involved a novel monoclonal antibody, showed promise by targeting amyloid plaques, a hallmark of Alzheimer's pathology. This approach not only opens new avenues for treatment but also provides hope for millions of patients and their families. The scientific community is closely monitoring these developments as they could redefine therapeutic strategies for neurodegenerative diseases.Moving on to regulatory news, the FDA has recently granted approval to a groundbreaking gene therapy for hemophilia B. This therapy represents a significant milestone as it offers a potential one-time treatment to correct the genetic defect underlying the disorder. By delivering a functional copy of the gene necessary for clotting factor production, patients may experience reduced bleeding episodes and improved quality of life. This approval underscores the FDA's commitment to advancing personalized medicine and highlights the transformative potential of gene therapies in addressing rare genetic conditions.In oncology, we've seen exciting progress with a novel targeted therapy showing efficacy in treating advanced stages of lung cancer. The drug specifically inhibits a mutation found in non-small cell lung cancer, which is often resistant to conventional treatments. Clinical trials have reported improved survival rates and better tolerability compared to existing therapies, marking a significant step forward in precision oncology. As researchers continue to unravel the complexities of cancer genomics, targeted therapies like this one offer new hope for patients battling aggressive forms of cancer.The biotech industry is also witnessing a surge in collaborations aimed at expediting vaccine development. In light of recent global health challenges, several companies have entered strategic partnerships to leverage their combined expertise in mRNA technology. These collaborations aim to accelerate the production and distribution of vaccines for infectious diseases beyond COVID-19. By pooling resources and sharing technological advancements, these alliances have the potential to enhance our preparedness for future pandemics and improve global public health outcomes.Shifting focus to autoimmune diseases, a novel small molecule inhibitor has shown potential in managing rheumatoid arthritis symptoms more effectively than traditional treatments. This new drug targets specific pathways involved in inflammation without compromising immune function. Early clinical data suggests it could offer patients relief with fewer side effects, representing a promising addition to the therapeutic arsenal against chronic inflammatory conditions.In an intriguing development within regenerative medicine, researchers have made strides in bioengineered organs. A recent breakthrough involves creating functional liver tissue from stem cells, paving the way for future organ transplantation solutions. These lab-grown tissues have demonstrated essential liver functions in preclinical models, bringing us closer to addressing organ shortages and enhancing transplant success rates. The implications of such advancements extend far beyond liver disease, offering transformative possibilities for regenerative therapies across various medical fields.Turning our attention to antimicrobial resistance, an ever-pressing concern within global health, scientists have discovered a new class of antibiotics capable of combating multidrug-resistant bacteria. This discovery comes atSupport the show

Join Dr. Pinkston as she welcomes Erica Bacchus, author of the deeply personal book, A Promise Kept. Erica shares the extraordinary and heartbreaking story of her late husband, John, and his battle with early cognitive impairment consistent with Alzheimer's disease. This conversation delves into a highly controversial and often-unspoken topic: end-of-life choices in the face of neurodegenerative disease. Erica describes the difficulty of John's diagnosis, his profound desire to maintain agency and dignity, and the intense emotional journey she undertook as his caregiver. They discuss: The challenge of Alzheimer's and end-of-life options, particularly the catch-22 regarding mental capacity and current U.S. laws like Medical Assistance in Dying. The couple's decision to seek assistance at Dignitas in Switzerland and the seven-month, complex application process. The overwhelming emotional toll of caregiving, the isolation, and the importance of honoring a spouse's deeply held, personal beliefs about life, purpose, and death. Erica's story is a testament to unwavering love, shared independence, and the courage it takes to support a loved one's choice to have a peaceful, dignified end on their own terms.See omnystudio.com/listener for privacy information.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of significant updates that are shaping the future of healthcare, patient care, and drug development.The U.S. Food and Drug Administration has been particularly active recently, granting Johnson & Johnson a National Priority Review Voucher for its multiple myeloma drug combination. This move highlights the importance of J&J's treatment in addressing unmet needs within oncology, a field continuously striving for innovative solutions. These vouchers expedite the review process, reflecting a broader commitment to accelerating the availability of critical therapies for patients who need them most.Continuing with regulatory advancements, AstraZeneca and Daiichi Sankyo's Enhertu, in combination with Roche's Perjeta, has gained FDA approval as a first-line treatment for unresectable or metastatic HER2-positive breast cancer. This breakthrough is supported by late-stage study results demonstrating a 44% reduction in disease progression or death compared to standard care. The approval signifies not only progress in breast cancer therapeutics but also underscores the potential benefits of strategic collaborations in drug development. Such partnerships are increasingly vital as they aim to optimize therapeutic efficacy through shared expertise and resources.In contrast to these advancements, Pfizer is facing financial recalibrations with projected revenues for 2026 estimated to decline due to diminishing COVID-19 vaccine sales and patent expirations. This situation reflects broader industry challenges as companies navigate post-pandemic market dynamics and patent cliffs, forcing reevaluations of long-term strategies.On another front, Gilead Sciences continues to push boundaries in HIV treatment with a promising single-tablet regimen combining bictegravir and lenacapavir. This innovation targets underserved segments within the HIV market, offering streamlined treatment options that could enhance patient adherence and outcomes significantly.Shifting focus to obesity management, Novo Nordisk's oral semaglutide is emerging as a highly anticipated medication among primary care providers. This trend highlights a growing preference for oral GLP-1 therapies as convenient alternatives to injectable formulations, marking a shift in how obesity—a major public health concern—is managed.The importance of regulatory compliance remains evident as Novo Nordisk received an FDA warning letter concerning manufacturing issues at an Indiana site previously owned by Catalent. This incident underscores the necessity for rigorous quality control in pharmaceutical manufacturing, which can have far-reaching implications on operational dynamics and supply chains.The FDA is also pioneering efforts to incorporate real-world evidence into medical device submissions by opening pathways for extensive deidentified datasets from sources like national cancer registries and electronic health records. This policy shift aims to integrate diverse data sources into the evidentiary foundation for medical device evaluations, potentially fostering innovation within this sector.In line with collaborative efforts, Genentech has partnered with Caris Life Sciences in a multi-year agreement valued at up to $1.1 billion, emphasizing the strategic importance of integrating diagnostic advancements with therapeutic developments to achieve precision medicine goals.Meanwhile, Yarrow Bioscience has acquired an autoimmune thyroid disease drug from China's Gensci, exemplifying a growing trend of cross-border collaborations aimed at leveraging global innovation ecosystems to address diverse therapeutic areas. This acquisition is part of a $1.37 billion deal, reinforcing the globalization of biotech partnerships as companies seek access to novel therapeutics andSupport the show

Maria Barna is an authority on ribosomes – “life's most ancient and spectacular molecular machines.” Ribosomes make proteins in the body. There can be a thousand different types of ribosomes in a single cell, she says, each with a specific job to do. But sometimes things go awry and ribosomes get “hijacked,” leading to disease. Barna studies these “diabolical” variations to find new therapies to treat diseases ranging from cancer and COVID to Parkinson's. When diseases hit, it's all about the ribosomes, Barna tells host Russ Altman on this episode of Stanford Engineering's The Future of Everything podcast.Have a question for Russ? Send it our way in writing or via voice memo, and it might be featured on an upcoming episode. Please introduce yourself, let us know where you're listening from, and share your question. You can send questions to thefutureofeverything@stanford.edu.Episode Reference Links:Stanford Profile: ​​Maria BarnaConnect With Us:Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads / Bluesky / MastodonConnect with School of Engineering >>> Twitter/X / Instagram / LinkedIn / FacebookChapters:(00:00:00) IntroductionRuss Altman introduces guest Maria Barna, a professor of genetics at Stanford University.(00:04:21) Origins of Ribosome ResearchMaria explains why ribosomes became the focus of her work.(00:06:14) Ribosome Function and ScaleRibosomes' functions and the energy required for their production.(00:08:28) Ribosomes as MachinesHow ribosomes influence which proteins are produced and when.(00:09:48) Ribosome RegulationThe regulatory layers within ribosomes and their possible variants.(00:14:35) Ribosomes and DiseaseHow ribosomal dysfunction is linked to a wide range of diseases.(00:18:16) Ribosome Mutations and DevelopmentCongenital disorders that can be attributed to specific ribosomal mutations.(00:20:44) RNA vs. Protein OutputWhy RNA measurements alone do not accurately predict protein levels.(00:24:16) Designing Ribosomes for TherapyThe potential of using engineered ribosomes for target therapies.(00:26:16) Small-Molecule Ribosome ModulatorsScreening compounds that may enhance ribosome activity for treatments.(00:28:39) Future Ribosome ProfilingIsolating individual ribosomes to understand their specific roles.(00:30:35) Future In a MinuteRapid-fire Q&A: scientific progress, community, and alternative career interest.(00:34:01) Conclusion Connect With Us:Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads / Bluesky / MastodonConnect with School of Engineering >>>Twitter/X / Instagram / LinkedIn / Facebook Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this week's episode of BizNinja Entrepreneur Radio, we're celebrating a birthday — and having our minds blown at the same time.I sat down with Eric Collett, founder of A Mind for All Seasons, to talk about one of the most overlooked assets in entrepreneurship: your brain. Not your mindset. Not productivity hacks. We're talking about the hardware — the biology, energy production, inflammation, and metabolic function behind every thought, decision, and action.Eric spent 16 years running assisted living and memory care communities, became obsessed with neurodegenerative diseases, and eventually built a science-backed system that helps people improve cognitive performance, stabilize mental health, and in some cases even reverse symptoms of dementia.This conversation goes deep. We're unpacking everything from why your “brain fog” isn't random… to how concussions, hormones, inflammation, and even cold sores can sabotage your mental clarity… to why Alzheimer's may actually be optional for this generation.Yes — optional. Let that sit for a minute.If you've ever felt stuck, unfocused, emotionally drained, or like your hardware just isn't keeping up with your software… this episode might be a turning point.Key TakeawaysWhy protecting your brain is the #1 success lever for entrepreneursThe real difference between “software” (skills) and “hardware” (your biology)Why brain fog has 15–30 measurable causes — and no one-size-fits-all supplementHow Eric went from executive director to quitting his job in three days to start his companyWhy Alzheimer's is now considered preventable — and what that means for youThe surprising link between inflammation, concussions, mental health, and cognitive declineHow personalized brain evaluations uncover hidden “holes in the ship”Why many people self-sabotage by withholding information from doctorsHow Eric helped transform the mental health of a young suicidal student by uncovering a clue she didn't think matteredWhat it means to “save a million brains” — and how you can take charge of your ownChapters00:00 Introduction and Birthday Celebration01:41 Early Entrepreneurial Spirit02:55 The Importance of Brain Health05:01 Transitioning to Brain Health Advocacy09:40 Understanding Brain Function and Misconceptions12:30 Personalized Approaches to Brain Health18:24 Success Stories in Brain Health22:32 Addressing Mental Health Across Ages26:49 Conclusion and Future Aspirations

Send us a textGood morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of impactful events and breakthroughs that are shaping patient care and drug development.The U.S. Food and Drug Administration recently granted early approval for a combination therapy using Padcev and Keytruda for the perioperative treatment of bladder cancer, a decision made months ahead of schedule. This approval represents a significant advancement in the therapeutic landscape for this type of cancer, offering new hope to patients who have had limited treatment options. The combination of these two therapies underscores the growing trend of integrating multiple mechanisms of action to tackle complex diseases like cancer more effectively. It also highlights the potential of combination therapies to provide enhanced clinical benefits by leveraging different therapeutic targets.In another notable development, Merck's partner Kelun announced successful Phase 3 trial results for an antibody-drug conjugate combined with Keytruda in treating PD-L1-positive non-small cell lung cancer (NSCLC). The trial results demonstrated statistically significant improvements in progression-free survival compared to Keytruda alone. This finding reinforces the expanding role of antibody-drug conjugates in oncology and emphasizes the importance of biomarker-driven therapies in personalizing cancer treatment. These advancements reflect a broader industry shift towards precision medicine, which aims to improve patient outcomes by tailoring treatments based on individual patient profiles.Meanwhile, Novo Nordisk experienced setbacks as its shares fell nearly 9% following two unsuccessful Phase 3 trials of semaglutide for Alzheimer's disease. Despite these disappointing results, this outcome highlights the persistent challenges and complexities inherent in developing therapies for neurodegenerative diseases—areas where unmet needs remain substantial. The market's reaction reflects investor sensitivity to clinical trial outcomes, particularly in high-stakes areas like Alzheimer's where breakthroughs are eagerly anticipated.Switching gears to AstraZeneca, the company is making a strategic move by expanding its manufacturing capabilities with a $2 billion investment in Maryland. This expansion reflects an ongoing trend among pharmaceutical companies to enhance their production infrastructure, driven by increasing demand for biologics and complex therapeutics. Such investments are crucial for supporting large-scale production needs and ensuring robust supply chains that are essential for meeting global health demands.In regulatory news, a collective letter from biotech CEOs addressed to FDA director Marty Makary has raised concerns about regulatory stability in the U.S., with 82% of biopharma respondents expressing apprehension over the FDA's ability to function predictably. This plea underscores how regulatory volatility can hinder innovation and emphasizes the importance of consistent policies that support long-term research and development efforts.In clinical trial updates, Bayer's oral FXIa inhibitor asundexian has shown promise in reducing stroke risk during Phase 3 trials. These findings revive interest in FXIa inhibitors as potentially blockbuster drugs after previous setbacks in this class. This development illustrates ongoing efforts to identify novel anticoagulant therapies that balance efficacy and safety, offering new hope for improved therapeutic options.Now turning our attention to Johnson & Johnson's recent setback with their anti-tau antibody posdinemab in a phase 2 trial targeting Alzheimer's disease. The trial was unable to demonstrate a significant slowing of clinical decline, leading JSupport the show

Clinical Pharmacist, Author, Board-Certified Clinical Nutritionist, and Health Expert Jim LaValle details the many health benefits of aged garlic extract, particularly its impact on periodontal disease. He reveals exciting new research findings that show Kyolic Aged Garlic Extract supplements can significantly reduce periodontal pocket depth -- a key indicator of gingivitis and periodontal disease progression. He also highlights the role of aged garlic extract in reducing inflammation and improving gum health, which in turn has significant implications for cardiovascular and cognitive health. The conversation also touches on various formulations of aged garlic extract available from Kyolic, the importance of integrative approaches to health and wellness, and updates on the latest trends in anti-aging medicine, including peptides and GLP-1 agonists.

Dr. Hoffman continues his conversation with clinical pharmacist, author, board-certified clinical nutritionist, and health expert Jim LaValle on the many health benefits of aged garlic extract.

Acting out dreams during sleep is an early warning sign of Parkinson's or dementia with Lewy bodies, offering a window for early detection and prevention Advanced MRI scans now reveal that your brain's waste-clearing system slows down years before symptoms like tremors, stiffness, or memory loss appear One study found that people with impaired brain waste clearance were more likely to develop Parkinson's, while another discovered that excess fluid between brain cells predicted future dementia These findings show that subtle changes in brain fluid balance — not just loss of dopamine or brain shrinkage — predict who develops neurodegenerative disease and how fast it progresses Supporting your brain's "cleaning system" through deep sleep, regular movement, hydration, and toxin avoidance helps protect memory, balance, and mental clarity for life

View the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter's Weekly Newsletter In this special episode, Peter provides a comprehensive introduction to longevity, perfect for newcomers or those looking to refresh their knowledge. He lays out the foundational concepts of lifespan, healthspan, and the marginal decade. Additionally, Peter discusses the four main causes of death and their prevention, as well as detailing the five key strategies in his longevity toolkit to improve lifespan and healthspan. Detailed show notes provide links for deeper exploration of these topics, making it an ideal starting point for anyone interested in understanding and improving their longevity. We discuss: Key points about starting exercise as an older adult [2:45]; Overview of episode topics and structure [1:45]; How Peter defines longevity [3:45]; Why healthspan is a crucial component of longevity [11:15]; The evolution of medicine from medicine 1.0 to 2.0, and the emergence of medicine 3.0 [15:30]; Overview of atherosclerotic diseases: the 3 pathways of ASCVD, preventative measures, and the impact of metabolic health [26:00]; Cancer: genetic and environmental factors, treatment options, and the importance of early and aggressive screening [33:15]; Neurodegenerative diseases: causes, prevention, and the role of genetics and metabolic health [39:30]; The spectrum of metabolic diseases [43:15]; Why it's never too late to start thinking about longevity [44:15]; The 5 components of the longevity toolkit [46:30]; Peter's framework for exercise—The Centenarian Decathlon [47:45]; Peter's nutritional framework: energy balance, protein intake, and more [58:45]; Sleep: the vital role of sleep in longevity, and how to improve sleep habits [1:08:30]; Drugs and supplements: Peter's framework for thinking about drugs and supplements as tools for enhancing longevity [1:13:30]; Why emotional health is a key component of longevity [1:17:00]; Advice for newcomers on where to start on their longevity journey [1:19:30]; and More. Connect With Peter on Twitter, Instagram, Facebook and YouTube

New study suggests taking thyroid medication WITH food may be just as good as taking it on an empty stomach; Natural support for Parkinson's Disease; Reviving the lost art of handwriting may be key to kid's learning; Dr. Jeffrey Bland does a deep dive on why not all fish oils are alike.

“When I was in medical school, no one had even heard of mitochondrial disease. Today, every student who graduates here knows what it is and has seen a patient with it,” says Dr. Mary Kay Koenig, director of the Center for the Treatment of Pediatric Neurodegenerative Disease at UTHealth Houston McGovern Medical School. That remarkable change in awareness has been accompanied by advances in genetic sequencing, the development of clinical guidelines, and the emergence of potential treatments in some forms of mitochondrial disease. In fact, Dr. Koenig's multidisciplinary team at UTHealth's Mitochondrial Center of Excellence has been a key player in clinical trials that may yield the first FDA-approved treatments for it. As you'll learn in this Year of the Zebra conversation with host Michael Carrese, her work in neurodegenerative diseases also includes tuberous sclerosis, where advanced therapies have replaced the need for repeated surgeries, and Leigh Syndrome, which has seen improvements in diagnoses and supportive therapies leading to better quality of life for patients.  Tune in as Dr. Koenig reflects on an era of progress in the space, the rewards of balancing research, teaching and patient care, and the need for more clinicians to center listening, humility and honesty in their approach to caring for rare disease patients and their  families.Mentioned in this episode:Mitochondrial Center of ExcellenceCenter for the Treatment of Pediatric Neurodegenerative Disease If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

Kristen is an Associate Professor at The Jackson Laboratory where her research focuses on the effects of age on brain function and dementia risk. As a first-generation college student, Kristen's path to doing cutting edge basic research is both inspirational and informative. Kristen  was one of the 5 Minute Genius™ speakers at this past year's Maine Science Festival; you can see her talk on our YouTube channel.This conversation was recorded in June 2025.  ~~~~~The Maine Science Podcast is a production of the Maine Discovery Museum. It is recorded at Discovery Studios, at the Maine Discovery Museum, in Bangor, ME. The Maine Science Podcast is hosted and executive produced by Kate Dickerson; edited and produced by Scott Loiselle. The Discover Maine theme was composed and performed by Nick Parker. To support our work: https://www.mainediscoverymuseum.org/donate. Find us online:Maine Discovery MuseumMaine Discovery Museum on social media: Facebook Instagram LinkedIn Bluesky Maine Science Festival on social media: Facebook Instagram LinkedInMaine Science Podcast on social media: Facebook Instagram © 2025 Maine Discovery Museum

You've seen the headlines about new blood tests and treatments for Alzheimer's, Parkinson's, and ALS, but what's the science behind those breakthroughs? In this episode, HudsonAlpha scientists Ben Henderson, PhD, and Bri Rogers, PhD, break down the role of biomarkers and genetics in early detection and treatments of neurodegenerative diseases. Discover how research being conducted today is creating real hope for tomorrow.To go behind the scenes and learn more about this episode, visit “Beyond the Headlines: How Biomarkers and Genetics are Changing Neurodegenerative Disease Research.” If you prefer to watch your podcasts, head over to our Youtube channel. Thanks for listening! We're now on YouTube- follow us here. To receive episode updates and bonus material, subscribe to our mailing list here.

Send us a textGenetic & environmental factors that affect brain health, including why people age faster in outer space. (Note: technical difficulties affected the audio quality of this recording somewhat)Episode Summary: Dr. Jacob Raber explains how apolipoproteins, particularly ApoE, influence brain health and disease risk; their role in cholesterol metabolism, Alzheimer's disease, and responses to environmental stressors like radiation and viral infections; interplay between genetics, diet, and lifestyle factors, highlighting how these affect cognitive function and resilience to stress; research into space radiation, the gut-brain axis, and potential interventions for neurodegenerative diseases.About the guest: Jacob Raber, PhD, is a neuroscientist at Oregon Health & Science University (OHSU) in Portland, where he leads a lab studying genetic and environmental influences on brain health, particularly using mouse models with human genes.Discussion Points:Apolipoproteins (ApoE2, E3, E4) are proteins involved in cholesterol and lipid metabolism in the brain, with ApoE4 increasing risks for Alzheimer's and cardiovascular disease.ApoE4 carriers may face higher risks for cognitive decline but could have advantages in specific contexts, like fertility or certain infections.Environmental stressors, such as space radiation and viral infections like West Nile, can exacerbate oxidative stress, impacting brain health.The gut microbiome influences brain function indirectly via the gut-liver-brain axis, with ongoing studies exploring its role in Alzheimer's and traumatic brain injury.Lifestyle factors like diet, exercise, and sleep are critical for brain health, potentially mitigating genetic risks like ApoE4.Statins, commonly used for cholesterol management, may impair learning in healthy animals, suggesting context-dependent effects.Research into space radiation reveals potential therapeutic applications, such as using heavy ion radiation for cancer treatment.Genetic variations, including ethnicity and sex, influence ApoE-related disease risks, with women and certain populations showing higher Alzheimer's susceptibility.Chronic low-level stressors, like air pollution, may pose greater risks to brain health than acute exposures due to insufficient activation of protective mechanisms.Related content:M&M 165: PUFAs in Brain Health & Disease, Dietary Fats, Brain Lipids, Nutrition | Richard Bazinet*Not medical adviceSupport the showAffiliates: Seed Oil Scout: Find restaurants with seed oil-free options, scan food products to see what they're hiding, with this easy-to-use mobile app. KetoCitra—Ketone body BHB + electrolytes formulated for kidney health. Use code MIND20 for 20% off any subscription (cancel anytime) Lumen device to optimize your metabolism for weight loss or athletic performance. Code MIND for 10% off SiPhox Health—Affordable at-home blood testing. Key health markers, visualized & explained. Code TRIKOMES for a 20% discount. For all the ways you can support my efforts

Nutritionist Leyla Muedin discusses recent advancements in the detection and prevention of Alzheimer's disease. Topics include the new FDA-approved Lumipulse blood test, the role of a ketogenic diet in improving mitochondrial health, and the significance of lifestyle changes such as social and cognitive activities. The episode also highlights promising research from the University of California Irvine on using natural compounds like nicotinamide and EGCG to rejuvenate aging brain cells and address the buildup of Alzheimer's-associated proteins. Leyla also provides insights into the difference between Alzheimer's and general dementia and emphasizes the importance of accurate diagnosis and appropriate treatments.

Nutritionist Leyla Muedin discusses the critical role of mitochondrial health throughout the lifespan, citing Dr. Jeffrey Bland's insights on mitochondria as a cornerstone of 21st-century health. The episode explores the benefits of ketosis and the ketogenic diet, particularly in supporting neurological health and conditions like epilepsy, Alzheimer's, and multiple sclerosis. Leyla highlights how ketogenic diets stimulate mitochondrial biogenesis and improve mitochondrial function while addressing potential contraindications for specific populations. The importance of a functional medicine approach and personalized interventions is emphasized for optimal health outcomes.

Description: In the third and final episode of the healthspan series, Dr. Erin Faules and Dr. Jeff Graham explore the intersection between neurodegenerative disease and metabolic dysfunction—two often-connected drivers of decline. They discuss early detection strategies, the role of genetics, and insulin resistance, and emerging clinical tools to assess and reduce long-term risk. Key Topics Covered: Distinguishing normal aging from neurodegenerative disease Early signs of cognitive decline and how to detect them The role of APOE-4 and other genes in Alzheimer's risk Metabolic dysfunction as a driver of brain aging ("Type 3 diabetes") Blood-based biomarkers: phospho-tau, NFL, CRP, fasting insulin, and more Lifestyle interventions: sleep, strength training, CGMs, circadian-aligned eating Tools like CNS Vital Signs, PET scans, and neuroquant MRIs Supplements and prescriptions: Omega-3s, creatine, berberine, GLP-1s, inositol Connecting muscle mass to glucose control and long-term healthspan